JP2002501054A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002501054A5 JP2002501054A5 JP2000528545A JP2000528545A JP2002501054A5 JP 2002501054 A5 JP2002501054 A5 JP 2002501054A5 JP 2000528545 A JP2000528545 A JP 2000528545A JP 2000528545 A JP2000528545 A JP 2000528545A JP 2002501054 A5 JP2002501054 A5 JP 2002501054A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 cyano, hydroxyl Chemical group 0.000 description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 5
- 150000001602 bicycloalkyls Chemical group 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- XLQRIUSFTHXJOG-QFIPXVFZSA-N (2s)-2-(naphthalen-1-ylsulfonylamino)-3-[[4-[3-oxo-3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)propyl]benzoyl]amino]propanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C2=CC=CC=C2C=CC=1)NC(=O)C(C=C1)=CC=C1CCC(=O)NC1=NCCCN1 XLQRIUSFTHXJOG-QFIPXVFZSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- 150000001450 anions Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1248998A | 1998-01-23 | 1998-01-23 | |
| US09/012,489 | 1998-01-23 | ||
| PCT/EP1999/000242 WO1999037621A1 (en) | 1998-01-23 | 1999-01-16 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002501054A JP2002501054A (ja) | 2002-01-15 |
| JP2002501054A5 true JP2002501054A5 (enExample) | 2006-03-02 |
Family
ID=21755208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000528545A Abandoned JP2002501054A (ja) | 1998-01-23 | 1999-01-16 | 骨吸収の阻害剤として及び細胞接着の阻害剤としての新規のスルホンアミド誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1049677A1 (enExample) |
| JP (1) | JP2002501054A (enExample) |
| KR (1) | KR20010034319A (enExample) |
| CN (1) | CN1177832C (enExample) |
| AP (1) | AP1269A (enExample) |
| AR (1) | AR014456A1 (enExample) |
| AU (1) | AU752882B2 (enExample) |
| BG (1) | BG104630A (enExample) |
| BR (1) | BR9907735A (enExample) |
| CA (1) | CA2318221A1 (enExample) |
| EA (1) | EA003102B1 (enExample) |
| HR (1) | HRP20000493A2 (enExample) |
| HU (1) | HUP0100520A3 (enExample) |
| ID (1) | ID26219A (enExample) |
| IL (1) | IL137423A0 (enExample) |
| NO (1) | NO318795B1 (enExample) |
| NZ (1) | NZ505613A (enExample) |
| PL (1) | PL341871A1 (enExample) |
| SK (1) | SK10632000A3 (enExample) |
| TR (1) | TR200002160T2 (enExample) |
| TW (1) | TWI247742B (enExample) |
| UA (1) | UA63990C2 (enExample) |
| WO (1) | WO1999037621A1 (enExample) |
| YU (1) | YU47200A (enExample) |
| ZA (1) | ZA99476B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000006169A1 (en) * | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP1028114A1 (en) | 1999-02-13 | 2000-08-16 | Aventis Pharma Deutschland GmbH | Novel guanidine derivatives as inhibitors of cell adhesion |
| EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
| EP1065207A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| EP1070707A1 (en) * | 1999-07-21 | 2001-01-24 | Aventis Pharma Deutschland GmbH | 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
| EP1108721A1 (en) | 1999-12-15 | 2001-06-20 | Aventis Pharma Deutschland GmbH | Thienylalanine derivatives as inhibitors of cell adhesion |
| WO2001047874A1 (en) * | 1999-12-24 | 2001-07-05 | Smithkline Beecham P.L.C. | (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
| FR2808798A1 (fr) * | 2000-05-09 | 2001-11-16 | Hoechst Marion Roussel Inc | Nouveaux derives antagonistes du recepteur de la vitronectine |
| FR2847254B1 (fr) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| AU2005223356B2 (en) * | 2004-03-24 | 2012-05-17 | Takeda Pharmaceutical Company Limited | New compounds for the inhibition of angiogenesis and use of thereof |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| GB0412553D0 (en) * | 2004-06-04 | 2004-07-07 | Univ Aberdeen | Therapeutic agents for the treatment of bone conditions |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| FR2873585B1 (fr) * | 2004-07-27 | 2006-11-17 | Aventis Pharma Sa | Nouvelles formulations galeniques de principes actifs |
| GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| GB0817208D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | Therapeutic apsap compounds and their use |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| JP6649902B2 (ja) | 2014-05-30 | 2020-02-19 | ファイザー・インク | 選択的アンドロゲン受容体モジュレーターとしてのカルボニトリル誘導体 |
| ES2899852T3 (es) | 2014-12-17 | 2022-03-15 | Pimco 2664 Ltd | Compuestos de N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencenosulfonamida y N-(-4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)-bencenosulfonamida y su uso terapéutico |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10501222A (ja) * | 1994-05-27 | 1998-02-03 | メルク エンド カンパニー インコーポレーテッド | 破骨細胞仲介骨吸収を抑制するための化合物 |
| JP3895792B2 (ja) * | 1995-12-08 | 2007-03-22 | プロスケリア・エス・ア・エス | 骨形成促進剤 |
-
1999
- 1999-01-16 HU HU0100520A patent/HUP0100520A3/hu unknown
- 1999-01-16 HR HR20000493A patent/HRP20000493A2/hr not_active Application Discontinuation
- 1999-01-16 ID IDW20001407A patent/ID26219A/id unknown
- 1999-01-16 UA UA2000084983A patent/UA63990C2/uk unknown
- 1999-01-16 PL PL99341871A patent/PL341871A1/xx unknown
- 1999-01-16 CN CNB998040894A patent/CN1177832C/zh not_active Expired - Fee Related
- 1999-01-16 AU AU25181/99A patent/AU752882B2/en not_active Ceased
- 1999-01-16 NZ NZ505613A patent/NZ505613A/xx unknown
- 1999-01-16 BR BR9907735-3A patent/BR9907735A/pt not_active IP Right Cessation
- 1999-01-16 SK SK1063-2000A patent/SK10632000A3/sk unknown
- 1999-01-16 EA EA200000785A patent/EA003102B1/ru not_active IP Right Cessation
- 1999-01-16 AP APAP/P/2000/001863A patent/AP1269A/en active
- 1999-01-16 YU YU47200A patent/YU47200A/sh unknown
- 1999-01-16 JP JP2000528545A patent/JP2002501054A/ja not_active Abandoned
- 1999-01-16 WO PCT/EP1999/000242 patent/WO1999037621A1/en not_active Ceased
- 1999-01-16 TR TR2000/02160T patent/TR200002160T2/xx unknown
- 1999-01-16 EP EP99904789A patent/EP1049677A1/en not_active Withdrawn
- 1999-01-16 IL IL13742399A patent/IL137423A0/xx unknown
- 1999-01-16 KR KR1020007008041A patent/KR20010034319A/ko not_active Abandoned
- 1999-01-16 CA CA002318221A patent/CA2318221A1/en not_active Abandoned
- 1999-01-22 ZA ZA9900476A patent/ZA99476B/xx unknown
- 1999-01-29 AR ARP990100244A patent/AR014456A1/es not_active Application Discontinuation
- 1999-04-30 TW TW088100862A patent/TWI247742B/zh active
-
2000
- 2000-07-21 NO NO20003765A patent/NO318795B1/no unknown
- 2000-07-21 BG BG104630A patent/BG104630A/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002501054A5 (enExample) | ||
| JP2001526271A5 (enExample) | ||
| JP2002515500A5 (enExample) | ||
| RU2265599C2 (ru) | Кристаллические соли 7-[4-(4-фторфенил)-6-изопропил-2-[метил (метилсульфонил) амино]пиримидин-5-ил]-(3r,5s)-3,5-дигидроксигепт-6-еновой кислоты, способ их получения и фармацевтическая композиция | |
| JP2002536438A5 (enExample) | ||
| PL181723B1 (pl) | Pochodne iminowe PL PL PL | |
| JP2010090128A (ja) | 結晶質の化合物ビス［（ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシ−６−ヘプテン酸］カルシウム塩 | |
| JP2008518053A5 (enExample) | ||
| JP2017504576A5 (enExample) | ||
| JP2010504978A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2018509438A5 (enExample) | ||
| JP2001509810A (ja) | Ｍｍｐインヒビターとしてのビス−スルホンアミドヒドロキサム酸 | |
| JPH06509798A (ja) | 新規ピラジン誘導体、それらの製造及び使用 | |
| JP3539926B2 (ja) | 抗ウイルス性ピリミジンジオン誘導体及びそれらの製造方法 | |
| WO1997032863A1 (en) | Thiazolidine-2,4-dione derivatives | |
| JP2008524210A5 (enExample) | ||
| JP2018501268A (ja) | チゾキサニドホスフェート及びアルカンスルホネート並びにその医薬用途 | |
| TW200808728A (en) | Method of preparing 4-halogenated quinoline intermediates | |
| KR20010089168A (ko) | 퀴나졸린 유도체 및 이의 약제학적 용도 | |
| JP2007531717A5 (enExample) | ||
| CA2577288A1 (en) | Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| US4496584A (en) | Amidine derivatives with anti-complement activity | |
| WO2003024946A2 (en) | Oxamate derivatives containing a variously substituted nitrogen heterocycle | |
| WO2006133654B1 (fr) | Utilisation d'inhibiteur nf-$g(k)b pour le traitement de diverses maladies |